“Having lived and worked overseas for 5 years, I feel I have a great connection to other cultures. It is a passion of mine to offer new innovative products and ideas, as well as learn from so many different cultures with their ideas,” -- Patrick Farley, CEO, Enso Discoveries, LLC.
MANHATTAN, Kan. (PRWEB) October 22, 2020
Enso Discoveries, LLC proudly announces its most recent international expansion into Costa Rica with the leading “Pan Latin American Distributor.” This is just one of three major global business developments that the American based biotech company has secured or enhanced during these uncertain times.
“We are very excited to partner with the premier “Pan Latin American” distribution organization in Costa Rica. Our partner has an extensive track record of success in both the veterinary and human medical markets, which will provide both our veterinary and new human health division, Enso Doctors, LLC, an opportunity to grow, along with providing our new partner a unique and prosperous opportunity,” explains Patrick Farley, CEO, Enso Discoveries, LLC.
In addition to a Latin American partnership, over the last few months, Enso Discoveries has been completing an initial assessment required by its new EU partner, based out of Germany. This means the company will be soon entering the EU markets with both the patented PRP (Platelet Rich Plasma) and PRF (Platelet Rich Fibrin) products that are currently distributed in the United States. Both products are rapidly becoming the choice for medical professions due to the ease of use, no new expensive capital needed, science-backed information, and all-inclusive kits that have made these once exclusive services now very affordable to all.
Enso Discoveries is also very proud to announce a new extended 2-year agreement with its Asian veterinary partners that will take the company into 2023, offering Board Certified Histopathology Interpretations. As the company has proven over the last two years to its current Asian partners that there is no substitute for quality interpretations, it anticipates case volume projections to be three to four times that of the current. The current market continues to expand rapidly and Enso Discoveries’ partners purposely direct more cases to their lab for the best in class quality interpretations.
“With a 24-hour or less turnaround time for most cases, we are proud to be helping give veterinarians the ability to make better, faster decisions in an effort to treat their clients' beloved pets,” says Farley, “As we drive each and every day here in the US to deliver our exceptional products, it is very apparent the demand outside of our country for our unique products is growing rapidly. We remain very excited to deliver the highest quality, most affordable products, to better the health of both animals and humans around the world.”
With the goal of improving quality of life while generating service-based revenues, Enso Discoveries has taken the lead in accessible, unique, affordable and validated regenerative medicine products with Rebound PRP and Rebound PRF in the US and now abroad. Both Rebound PRP and Rebound PRF were designed with veterinarians and physicians in mind. They were validated in a major university, patent-pending and are adjustable therapies to produce a customized amount of PRP or PRF that a patient might need for optimum healing.
Enso Discoveries, LLC is a biotech company focused on enhancing lives through the development of relevant, cost-effective, novel technology that allows our valued customers, to offer better service to all patients and keep their hard-earned business in house. We support our products and services with scientific proof, national distribution partners, and a worldwide network of industry experienced contacts. Ask your distributor about Enso Discoveries, LLC products such as Rebound PRP™ and Rebound PRF® or learn more at http://www.ensodiscoveries.com or http://www.EnsoDoctors.com.